Acromegaly, inflammation and cardiovascular disease: a review.
Thalijn L C WoltersMihai M NeteaNiels P RiksenAdrianus R M M HermusRomana T Netea-MaierPublished in: Reviews in endocrine & metabolic disorders (2021)
Acromegaly is characterized by Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) excess. Uncontrolled acromegaly is associated with a strongly increased risk of cardiovascular disease (CVD), and numerous cardiovascular risk factors remain present after remission. GH and IGF-1 have numerous effects on the immune and cardiovascular system. Since endothelial damage and systemic inflammation are strongly linked to the development of CVD, and have been suggested to be present in both controlled as uncontrolled acromegaly, they may explain the presence of both micro- and macrovascular dysfunction in these patients. In addition, these changes seem to be only partially reversible after remission, as illustrated by the often reported presence of endothelial dysfunction and microvascular damage in controlled acromegaly. Previous studies suggest that insulin resistance, oxidative stress, and endothelial dysfunction are involved in the development of CVD in acromegaly. Not surprisingly, these processes are associated with systemic inflammation and respond to GH/IGF-1 normalizing treatment.
Keyphrases
- growth hormone
- oxidative stress
- cardiovascular disease
- cardiovascular risk factors
- type diabetes
- end stage renal disease
- metabolic syndrome
- newly diagnosed
- chronic kidney disease
- dna damage
- disease activity
- diabetic rats
- ischemia reperfusion injury
- induced apoptosis
- systemic lupus erythematosus
- prognostic factors
- rheumatoid arthritis
- high fat diet
- endoplasmic reticulum stress
- replacement therapy